Rising Incidences Of Cancer Across Globe: Transformative Forces Shaping the Cancer Tumor Profiling Market Landscape in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Cancer Tumor Profiling Industry Market Size Be by 2025?
The overall valuation of the cancer tumor profiling sector has experienced swift expansion across recent periods, projected to escalate from a figure of $13 billion in the year 2024 up to $14.97 billion by 2025, reflecting a compound annual growth rate of 15.1%. This upward trajectory observed during the past timeframe is fundamentally driven by several key factors, including a rising prevalence of cancer cases globally, advancements in personalized medicine efforts and collaborative research endeavors, enhancements in both the diagnosis of cancer and methodologies for earlier identification, the broader accessibility of numerous therapies designed for specific targets, and legislative environments that favor the implementation of cancer profiling assessments.

What's the Long-Term Growth Forecast for the Cancer Tumor Profiling Market Size Through 2029?
Anticipation surrounds the cancer tumor profiling sector, projecting substantial escalation in its market size over the forthcoming years, with valuations poised to reach $25.12 billion by 2029, reflecting a compound annual growth rate (CAGR) of 13.8% throughout the projection timeframe; this upward trajectory is spurred by the spreading utilization of immunotherapy and immunoprofiling techniques in oncological care, breakthroughs in liquid biopsy and less invasive tumor characterization procedures, the increasing employment of single-cell sequencing for deeper tumor delineation, the proliferation of cancer screening and early diagnosis initiatives, alongside a rising need to profile uncommon and rare cancer subsets. Key developments shaping this period are characterized by the assimilation of tumor profiling into standard medical procedures, progress in multi-omics methodologies, the incorporation of artificial intelligence and machine learning for sophisticated data interpretation, advancements in crafting personalized medicine and targeted therapeutic strategies, and continued innovation within genomics and next-generation sequencing (NGS) platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

What Are the Key Growth Drivers Fueling the Cancer Tumor Profiling Market Expansion?
Driven by the escalating worldwide occurrence of cancer, the market for cancer and tumor profiling is anticipated to experience significant expansion in the future. This condition, characterized by the unchecked multiplication and dissemination of certain bodily cells to other sites, naturally leads to a greater need for cancer tumor profiling services, assisting clinicians in accurately assessing the extent of the illness. Supporting this trend, the American Cancer Society, a professional body situated in the United States, documented in 2024 that the nation recorded 2 million new cancer diagnoses, a noticeable increase from the 1.9 million new cases identified in 2023; consequently, this rising global prevalence of cancer serves as a primary catalyst propelling the expansion of the cancer and tumor profiling industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

What Are the Key Trends Driving Cancer Tumor Profiling Market Growth?
A prominent movement within the cancer and tumor profiling market is the escalating focus on research and development efforts. Leading enterprises in this domain are prioritizing R&D to satisfy market needs and strengthen their competitive standing. Illustratively, QIAGEN N.V., a prominent German entity specializing in sample and assay technologies for diverse applications including pharmaceutical progress, molecular diagnostics, applied testing, and scholarly investigation, publicized the attainment of CE-marking and the subsequent market introduction across Europe for its therascreen PIK3CA RGQ PCR Kit; this kit functions as an instrument to pinpoint breast cancer patients possessing PIK3CA gene mutations. This therascreen PIK3CA diagnostic is notable as the initial assay capable of detecting an activating mutation within the PIK3CA gene while simultaneously permitting analysis of genetic material derived from either circulating plasma samples or formalin-fixed, paraffin-embedded (FFPE) tissue specimens.

How Is the Cancer Tumor Profiling Market Segmented?
The cancer tumor profilingmarket covered in this report is segmented -

1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications

Subsegments:
1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

Which Companies Are Leading the Charge in Cancer Tumor Profiling Market Innovation?
Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

Which Regions Are Leading the Global Cancer Tumor Profiling Market in Revenue?
North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.